Cytokinetics, Incorporated (CYTK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 38.65 |
| Open | 38.16 |
| Bid | 38.81 x 800 |
| Ask | 38.78 x 1300 |
| Day's Range | 36.81 - 39.17 |
| 52 Week Range | 17.72 - 47.90 |
| Volume | |
| Avg. Volume | 925,791 |
| Market Cap | 3.274B |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.11 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.83 |
- GlobeNewswire
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2022 ALS Roundtables, the National Advocacy Conference and the ALS Focus survey program. Cytokinetics is also a Platinum Level Sponsor for initiatives led by The ALS Association Golden West Chapter for people with ALS in the Bay Area. “We are
- GlobeNewswire
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26, 2022. The presentation will be available for on-demand viewing beginning Tuesday, May 24, 2022 at 7:00 AM ET. Interested parties may access the pre-recorded presentation by visiting the Investors & Medi
- GlobeNewswire
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
FDA Plans to Convene Advisory Committee MeetingSOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil. Cytokinetics expects the FDA to inform it of the date and topics for the Adv
